Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)

NCT05183646 is registered in ClinicalTrials.gov with Dimerix Bioscience Pty Ltd as lead sponsor.

NCT NCT05183646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05183646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pivotal Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy and Safety of DMX-200 in Patients With Focal Segmental Glomerulosclerosis (FSGS) Who Are Receiving an Angiotensin II Receptor Blocker (ARB)
Lead sponsor
Dimerix Bioscience Pty Ltd
Phase
Phase 3
Overall status
Recruiting
Start date
May 30, 2022
Completion date
December 31, 2029
Enrollment
286 (estimated)
Sites
220

Conditions

As the registry lists them; a condition with its own page is linked.

fsgs